Młynarska Ewelina, Czarnik Witold, Dzieża Natasza, Jędraszak Weronika, Majchrowicz Gabriela, Prusinowski Filip, Stabrawa Magdalena, Rysz Jacek, Franczyk Beata
Department of Nephrocardiology, Medical University of Lodz, Ul. Zeromskiego 113, 90-549 Lodz, Poland.
Department of Nephrology, Hypertension and Family Medicine, Medical University of Lodz, Ul. Zeromskiego 113, 90-549 Lodz, Poland.
Int J Mol Sci. 2025 Jan 27;26(3):1094. doi: 10.3390/ijms26031094.
Type 2 diabetes mellitus (T2DM), a prevalent chronic disease affecting over 400 million people globally, is driven by genetic and environmental factors. The pathogenesis involves insulin resistance and β-cell dysfunction, mediated by mechanisms such as the dedifferentiation of β-cells, mitochondrial dysfunction, and oxidative stress. Treatment should be based on non-pharmacological therapy. Strategies such as increased physical activity, dietary modifications, cognitive-behavioral therapy are important in maintaining normal glycemia. Advanced therapies, including SGLT2 inhibitors and GLP-1 receptor agonists, complement these treatments and offer solid glycemic control, weight control, and reduced cardiovascular risk. Complications of T2DM, such as diabetic kidney disease, retinopathy, and neuropathy, underscore the need for early diagnosis and comprehensive management to improve patient outcomes and quality of life.
2型糖尿病(T2DM)是一种在全球影响超过4亿人的常见慢性病,由遗传和环境因素驱动。其发病机制涉及胰岛素抵抗和β细胞功能障碍,通过β细胞去分化、线粒体功能障碍和氧化应激等机制介导。治疗应基于非药物疗法。增加体育活动、饮食调整、认知行为疗法等策略对于维持正常血糖水平很重要。包括钠-葡萄糖协同转运蛋白2(SGLT2)抑制剂和胰高糖素样肽-1(GLP-1)受体激动剂在内的先进疗法补充了这些治疗方法,并提供了可靠的血糖控制、体重控制和降低心血管风险的效果。T2DM的并发症,如糖尿病肾病、视网膜病变和神经病变,凸显了早期诊断和综合管理以改善患者预后和生活质量的必要性。